These results demonstrate that HPR may promote tumour growth through coactivation of YAP and mTORC1 and that targeting the HPR using LNA can suppress breast cancer in a preclinical model (Fig. 7d and Supplement Fig. 5). This evidence concerns the gene HPR and breast carcinoma.